Madrigal Pharmaceuticals (MDGL) Operating Leases (2019 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Operating Leases for 8 consecutive years, with $5.9 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Operating Leases rose 30.92% year-over-year to $5.9 million; the TTM figure through Jun 2026 stood at $5.9 million (up 30.92% YoY), while the FY2025 annual figure was $6.7 million, up 561.2% from the prior year.
• Operating Leases advanced to $5.9 million in Q2 2026 per MDGL's latest filing, from $5.3 million in the prior quarter.
• Across five years, Operating Leases topped out at $6.7 million in Q4 2025 and bottomed at $71000.0 in Q3 2022.
• Historically, Operating Leases has averaged $2.4 million across 5 years, with a median of $1.2 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Leases plunged 85.54% — and 2023, when it soared 1763.38%.
• Madrigal Pharmaceuticals' Operating Leases stood at $71000.0 in 2022, then soared by 1570.42% to $1.2 million in 2023, then declined by 14.17% to $1.0 million in 2024, then surged by 561.2% to $6.7 million in 2025, then decreased by 12.0% to $5.9 million in 2026.
• Business Quant data shows MDGL's Operating Leases at $5.9 million in Q2 2026, $5.3 million in Q1 2026, and $6.7 million in Q4 2025.